Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Catheter-based cardiac cryoablation · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Catheter-based cardiac cryoablation | DEVICE | - |
Inclusion Criteria: * Symptomatic atrial flutter Exclusion Criteria: * Prior ablation * Contraindication to intervention * Poor general health
Catheter-based cardiac cryoablation is used for the treatment of atrial flutter, a type of abnormal heart rhythm. It is an investigational procedure being studied in a Phase 3 clinical trial to evaluate its safety and efficacy for this condition.
Catheter-based cardiac cryoablation is developed by Boston Scientific Corporation, a company traded on the New York Stock Exchange under the ticker symbol BSX. The company is conducting clinical research to evaluate this treatment for atrial flutter.
Catheter-based cardiac cryoablation is in Phase 3 clinical development. It is an investigational treatment for atrial flutter and has not yet been approved by regulatory authorities. A Phase 3 trial has been completed to assess its safety and efficacy.
Catheter-based cardiac cryoablation has one completed Phase 3 clinical trial, identified as NCT00113178. This trial, titled 'Safety and Efficacy of the CryoCor™ Cardiac Cryoablation System for the Treatment of Atrial Flutter,' enrolled 160 participants aged 18 years and older.
Catheter-based cardiac cryoablation is the procedure being evaluated in the clinical trial, which uses the CryoCor™ Cardiac Cryoablation System. The trial is designed to test the safety and efficacy of this system for treating atrial flutter.